Earlier Data, More Support: EMA Explains Priority Medicines Plan
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has confirmed that its proposed priority medicines initiative, PRIME, will be aimed at identifying at a much earlier stage new medicines that fulfil the current criteria for accelerated assessment – that is, those that could benefit patients who have no treatment options or that represent a major therapeutic advantage over existing products.
You may also be interested in...
Coronavirus Notebook: EMA Data Hack Aimed At 'Undermining Trust' In Vaccines, Russia Plans EU Sputnik V Filing Next Month
France has reported on side-effect reports concerning the Pfizer/BioNTech vaccine, and the World Health Organization has warned that plans to provide global equitable access to coronavirus vaccines are at risk.
UK Spending £2.9bn On Seven COVID-19 Vaccines
The UK government says it is on track to vaccinate the 15 million most vulnerable people by mid-February, and that a “major study” is under way to assess the potential impact of the new UK variant on vaccine efficacy.
Coronavirus Notebook: EU To Buy 30 Million Doses Of Valneva Vaccine, Russia To Issue Compulsory License For Remdesivir
The European Medicines Agency says hacked COVID-19 vaccine data has been leaked online, and Australia’s chief medical officer defends the Oxford/AstraZeneca vaccine against scientists’ claim that it is not effective enough.
Need a specific report? 1000+ reports available
Buy Reports